Retinal vein occlusion
Conditions
Sponsors
Guang'anmen Hospital, Chinese Academy of traditional Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) The patients who met the western medicine diagnosis standard of retinal vein occlusion and had definite bleeding; (2) Those who meet the syndrome differentiation criteria of blood stasis and collateral injury, yin deficiency and internal heat; (3) Patients within 3 months (excluding 3 months); (4) 35-75 years old; (5) Signing informed consent.
Exclusion criteria
Exclusion criteria: (1) Patients with retinal vein occlusion and blood deficiency; (2) The area of capillaries without perfusion of retinal vein occlusion was more than 5 disc diameters (PD) with neovascularization of disc, retina and iris, or the patients were treated by intraocular injection and laser therapy in the early stage; (3) Patients with diabetic retinopathy, retinal detachment, proliferative retinopathy, senile maculopathy, glaucoma, severe cataract, inflammatory retinopathy and other eye diseases that affect the efficacy judgment; (4) Eyeground hemorrhage caused by leukemia, trauma and other reasons; (5) Pregnant, preparing pregnant or lactating women; (6) Allergic constitution, especially allergic to fluorescein sodium injection; (7) Patients with hypertension but still high blood pressure (systolic blood pressure >=160 or diastolic blood pressure >=100mmhg), severe cardiopulmonary insufficiency and severe arrhythmia (rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia, type II and III atrioventricular block, etc.) after drug treatment; (8) In the patients with severe liver and kidney dysfunction, ALT and AST were more than 1.5 times of the upper limit of normal, Cr was more than 1.2 times of the upper limit of normal; (9) Patients with severe primary diseases such as digestive system and hematopoietic system; (10) Disabled patients (blind, deaf, dumb, mental disorders, mental disorders, etc.) as prescribed by law; (11) Those who participated in other clinical trials in the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual effect;Improvement of the area of eyeground bleeding; | — |
Secondary
| Measure | Time frame |
|---|---|
| Retinal circulation time of fundus fluorescein angiography;Evaluation of neovascularization;Evaluation of area without perfusion;Improvement of macular fovea thickness and total volume;TCM syndrome; | — |
Countries
China
Contacts
Public ContactWu Lie
Beijing Kangpaite Medical Science and Technique LTD.
Outcome results
None listed